Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 01, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Added to Russell 3000® Index

NEW HAVEN, Conn., July 01, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that the company has been added to the broad-market Russell 3000® Index...
June 18, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference

NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will...
June 10, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial

Total of 96 agitated patients and healthy volunteers have received multiple doses of BXCL501, a proprietary sublingual thin film On track to announce top line results from Phase 2 efficacy trial in...
June 06, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics CEO, Dr. Vimal Mehta to Participate in BIO International Convention Panel on Innovative Clinical Trial Designs

NEW HAVEN, Conn., June 06, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), announced today that Dr. Vimal Mehta, Chief Executive Officer and Founder of BTI,...
June 03, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces FDA Clearance of IND Application for Triple Combination in Pancreatic Cancer and CTA Acceptance for Double Combination in Aggressive Form of Prostate Cancer (tNEPC) for Lead Immuno-Oncology Program, BXCL701

• FDA clearance of IND for BXCL701 triple combination therapy with Nektar’s bempegaldesleukin and BAVENCIO® (avelumab, Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic cancer • MHRA (U.K....
May 31, 2019 16:05 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference

NEW HAVEN, Conn., May 31, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence...
May 20, 2019 07:30 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases

Phase 2 efficacy trial in agitated schizophrenia patients anticipated to commence imminently BXCL501 is a potential first-in-class selective alpha-2a receptor agonist, formulated as a proprietary...
May 13, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City

Management to unveil BXCL501 global development strategy and agitation franchise expansion Key Opinion Leaders to discuss acute agitation across multiple disease conditions Webcast scheduled from...
May 09, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference

NEW HAVEN, Conn., May 09, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present...
May 07, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update

On track to announce results in May 2019 from recently completed BXCL501 Phase 1 pharmacokinetic (bioavailability) and safety study Advanced manufacturing of BXCL501 thin film formulation for pivotal...